NGLY1 deficiency is a recently described autosomal recessive disorder, involved in deglycosylation of proteins, and for that reason grouped as the congenital disorders of deglycosylation together with the lysosomal storage disorders. The typical phenotype is characterized by intellectual disability, liver malfunctioning, muscular hypotonia, involuntary movements, and decreased or absent tear production. Liver biopsy demonstrates vacuolar amorphous cytoplasmic storage material. NGLY1 deficiency is caused by bi-allelic variants in NGLY1 which catalyzes protein deglycosylation. We describe five patients from two families with NGLY1 deficiency due to homozygosity for two novel NGLY1 variants, and compare their findings to those of earlier reported patients. The typical features of the disorder are present in a limited way, and there is intra-familial variability. In addition in one of the families the muscle atrophy and posture abnormalities are marked. These can be explained either as variability of the phenotype or as sign of slowly progression of features as the present affected individuals are older than earlier reported patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmg.2021.104146DOI Listing

Publication Analysis

Top Keywords

ngly1 deficiency
16
earlier reported
8
reported patients
8
ngly1
6
deficiency novel
4
novel variants
4
variants literature
4
literature review
4
review ngly1
4
deficiency described
4

Similar Publications

Development of new NGLY1 assay systems - toward developing an early screening method for NGLY1 deficiency.

Glycobiology

September 2024

Glycometabolic Biochemistry Laboratory, RIKEN Cluster for Pioneering Research (CPR), Riken, 2-1 Hirosawa, Wako Saitama 351-0198, Japan.

Cytosolic peptide: N-glycanase (PNGase/NGLY1 in mammals) is an amidase (EC:3.5.1.

View Article and Find Full Text PDF
Article Synopsis
  • The protein PNGase helps manage other proteins by getting rid of the bad ones in our cells.
  • A mutation in the gene for PNGase can lead to a condition called NGLY1 deficiency, which is not good for health.
  • Scientists found out more about a related protein called FBS2, which might be a good target for new drugs to help treat NGLY1 deficiency.
View Article and Find Full Text PDF

The cytoplasmic peptide:N-glycanase (NGLY1) is ubiquitously expressed and functions as a de-N-glycosylating enzyme that degrades misfolded N-glycosylated proteins. NGLY1 deficiency due to biallelic loss-of-function NGLY1 variants is an ultrarare autosomal recessive deglycosylation disorder with multisystemic involvement; the neurological manifestations represent the main disease burden. Currently, there is no treatment for this disease.

View Article and Find Full Text PDF

The conserved SKN-1A/Nrf1 transcription factor regulates the expression of proteasome subunit genes and is essential for maintenance of adequate proteasome function in animal development, aging, and stress responses. Unusual among transcription factors, SKN-1A/Nrf1 is a glycoprotein synthesized in the endoplasmic reticulum (ER). N-glycosylated SKN-1A/Nrf1 exits the ER and is deglycosylated in the cytosol by the PNG-1/NGLY1 peptide:N-glycanase.

View Article and Find Full Text PDF
Article Synopsis
  • * In a study involving 29 individuals, 90% reported ocular symptoms, with common issues being dryness, refractive errors, and infections; 62% used daily eye medications.
  • * The study highlights the importance of specialized eye care and examinations for early diagnosis and management of vision-related problems in people with NGLY1 deficiency.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!